Training programs in #celltherapy & #genetherapy through the International Society for Cell & Gene Therapy www.isctglobal.org/resources/tr...

The results from IOV-COM-202 cohort 1a vs previous Iovance TIL trials in checkpoint refractory melanoma patients plus the NCI Surgery Branch's dataset definitely bring into question where in the sequence of therapies TIL ACT should sit. #TILTherapy

1) Dr #Stephanie_Goff @ #NCI #SurgeryBranch Gives fantastic overview #TIL #adoptive #immunotherapy /Evolving landscape, challenges, what is the future 4 #melanoma @melanomaau.bsky.social
@melanomaresearch.bsky.social @impactmelanoma.bsky.social
@sitcancer.bsky.social
#Bridge2025
#FinishCancer

Glad to see Bluesky get added to Altmetric’s tracking. It will be interesting to see how Bluesky holds up long term for disseminating research.

Very thankful to have a great group of members in the lab that can keep projects running smoothly while I step away from the lab for a week to spend time with family adopting a new city as our own. This year was #Edinburgh plus a day trip to Rosslyn Chapel, Hadrian's Wall, and Vindolanda.

Great thread Anna. Thanks for sharing this work.

1/23 Big news for the #ObenaufLab! So excited to finally share our new study providing another puzzle piece, why immunotherapy fails in many tumors, now out in @Nature 🧵👇 www.nature.com/articles/s41...

CEF for human samples. Will give reactivity on practically every sample.

We're looking to recruit a postdoc with expertise in RNA biology to join our glyco-RNA team. Please share.

moffitt-cancer-center-careers.hctsportals.com/jobs/1808511...

Second Primary Malignancies after CAR T-Cell Therapy: A Systematic Review and Meta-analysis of 5,517 Lymphoma and Myeloma Patients AbstractPurpose:. Chimeric antigen receptor (CAR) T-cell therapy is a potent immunotherapy for hematologic malignancies, but patients can develop long-term adverse events, including second primary mal...

Link to paper - Second Primary Malignancies after CAR T-Cell Therapy: A Systematic Review and Meta-analysis of 5,517 Lymphoma and Myeloma Patients @mskcancercenter.bsky.social #CARTcells aacrjournals.org/clincancerre...

Very nice resource for anyone needing a starting point for figure illustration.

Beautiful day and a packed crowd this morning for the 5k start at #MilesforMoffitt @TILDevLab.bsky.social

With the #TurTILs this morning at Thunder Alley for #MilesforMoffitt 2024 @TILDevLab.bsky.social

Adding to the multitude of skyline pics in my feed with my recent trip to Tokyo. Here is one looking towards Mt Fuji from the Metropolitan Government Building along with the world’s largest projection mapping on the same building.

Pooled CRISPR screens with joint single-nucleus chromatin accessibility and transcriptome profiling - Nature Biotechnology MultiPerturb-seq profiles gene expression and chromatin accessibility in single-cell pooled CRISPR screen.

Pooled CRISPR screens with joint single-nucleus chromatin accessibility and transcriptome profiling go.nature.com/4hXER5O

It's that time again when we all crowd along the bay and take a morning run/walk for #CancerResearch. Looking forward to another year of #MilesforMoffitt with our #TILTherapy team, the #TurTILs. MilesforMoffitt.com

Seem to have received the collective migration memo over the weekend along with the rest of Med/Science Twitter. A little intro: #Immunology #Immunotherapy #ImmunoOncology #TCell #CellTherapy #TIL #Biotech #TranslationalResearch #CureCancer